open access

Vol 2, No 6 (2013)
Review
Published online: 2013-12-30
Get Citation

The efficacy and safety of DPP-4 inhibitors considering cardiovascular risk factors

Aleksandra Szymborska-Kajanek, Marta Wróbel, Dominika Rokicka, Anna Bożek, Krzysztof Strojek
Diabetologia Kliniczna 2013;2(6):220-225.

open access

Vol 2, No 6 (2013)
Review
Published online: 2013-12-30

Abstract

In most diabetic patients, cardiovascular diseases, especially myocardial infarction and cerebral stroke, remain the main cause of death. Thus, the control of risk factors, especially glycemic control, plays a key role in death prevention. Additional (other than hypoglycemic) effects of antidiabetic agents remain an open question. Currently available agents include the recently introduced class of DPP-4 inhibitors. Numerous clinical trials confirmed their efficacy in reducing glycemia and safety of use. There are reasons to argue that, in addition to hypoglycemic effect, inhibition of GLP-1 degradation may contribute to reducing the risk of cardiovascular complications. This paper is an overview of the present state of knowledge of the effect of GLP-1 and inhibition of its degradation on cardiovascular risk. The final settlement of this question will take place after publication of the results of large clinical trials assessing the effect ofDPP-4 inhibitors on the development of cardiovascular outcomes.

Abstract

In most diabetic patients, cardiovascular diseases, especially myocardial infarction and cerebral stroke, remain the main cause of death. Thus, the control of risk factors, especially glycemic control, plays a key role in death prevention. Additional (other than hypoglycemic) effects of antidiabetic agents remain an open question. Currently available agents include the recently introduced class of DPP-4 inhibitors. Numerous clinical trials confirmed their efficacy in reducing glycemia and safety of use. There are reasons to argue that, in addition to hypoglycemic effect, inhibition of GLP-1 degradation may contribute to reducing the risk of cardiovascular complications. This paper is an overview of the present state of knowledge of the effect of GLP-1 and inhibition of its degradation on cardiovascular risk. The final settlement of this question will take place after publication of the results of large clinical trials assessing the effect ofDPP-4 inhibitors on the development of cardiovascular outcomes.
Get Citation

Keywords

type 2 diabetes, hypoglycaemic agents, cardiovascular risk, DPP-4 inhibitors

About this article
Title

The efficacy and safety of DPP-4 inhibitors considering cardiovascular risk factors

Journal

Clinical Diabetology

Issue

Vol 2, No 6 (2013)

Pages

220-225

Published online

2013-12-30

Bibliographic record

Diabetologia Kliniczna 2013;2(6):220-225.

Keywords

type 2 diabetes
hypoglycaemic agents
cardiovascular risk
DPP-4 inhibitors

Authors

Aleksandra Szymborska-Kajanek
Marta Wróbel
Dominika Rokicka
Anna Bożek
Krzysztof Strojek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl